My watch list  


Systematic (IUPAC) name
N-[2-[4-[3-(1-methylethylamino) pyridin-2-yl] piperazin-1-yl] carbonyl-1H-indol-5-yl] methanesulfonamide
CAS number 136817-59-9
ATC code J05AG02
PubChem 5625
DrugBank APRD00149
Chemical data
Formula C22H28N6O3S 
Mol. mass 456.562 g/mol
Pharmacokinetic data
Bioavailability 85%
Protein binding 98%
Metabolism Hepatic (CYP3A4- and CYP2D6-mediated)
Half life 5.8 hours
Excretion Renal (51%) and fecal (44%)
Therapeutic considerations
Pregnancy cat.

B3(AU) C(US)

Legal status


Routes Oral

Delavirdine (DLV) (brand name Rescriptor®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by Pfizer. It is used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1. It is presented as the mesylate. The recommended dosage is 400 mg, three times a day.

Although delavirdine was approved by the U.S. Food and Drug Administration in 1997, its efficacy is lower than other NNRTIs, especially efavirenz, and it also has an inconvenient schedule. These factors have led the U.S. DHHS not to recommend its use as part of initial therapy.[1] The risk of cross-resistance across the NNRTI class, as well as its complex set of drug interactions, make the place of delavirdine in second-line and salvage therapy unclear, and it is currently rarely used.

Like ritonavir, delavirdine is an inhibitor of cytochrome P450 isozyme CYP3A4, and interacts with many medications. It should not be administered with a wide range of drugs, including amprenavir, fosamprenavir, simvastatin, lovastatin, rifampin, rifabutin, rifapentine, St John's wort, astemizole, midazolam, triazolam, ergot medications, and several medications for acid reflux.[1]

The most common adverse event is moderate to severe rash, which occurs in up to 20% of patients.[2] Other common adverse events include fatigue, headache and nausea. Liver toxicity has also been reported.


  1. ^ a b DHHS panel. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 4, 2006). (Available for download from AIDSInfo)
  2. ^ RESCRIPTOR® brand of delavirdine mesylate tablets. Product information.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Delavirdine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE